combination taxol + ifosfamide + mitoxantion in the treatment of advanced breast cancer

In a Phase II study, patients with advanced breast cancer resistant to antracyclines were treated with a combination of Paclitaxel, Ifosfamid and Mitoxantron. Paclitaxel was administered in the dose of 135 mg/m2 by 3 -hour infusion. Altogether 65 cycles in 15 patients were administered, for an overall response rate of 46,6%. The most frequent hematological toxicity was myelosupression, Non-haematological toxicities were never of clinical concern. The combination was found to be useful out patient's treatment in breast cancer patients resistant to antracyclines